Fenflor 300 mg/ml Solution for Injection for Pigs

Main information

  • Trade name:
  • Fenflor 300 mg/ml Solution for Injection for Pigs
  • Pharmaceutical form:
  • Solution for injection
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Fenflor 300 mg/ml Solution for Injection for Pigs
    Portugal
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • florfenicol
  • Therapeutic area:
  • Pigs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0291/001
  • Authorization date:
  • 14-04-2010
  • EU code:
  • UK/V/0291/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Revised:March2013

AN:01142/2012

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Fenflor300mg/mlsolutionforinjectionforpigs

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachmlcontains:

Activesubstance:

Florfenicol…………300mg

Excipients:

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Solutionforinjection

Alightyellowtoyellow,clear,viscousliquid.

4. CLINICALPARTICULARS

4.1Targetspecies

Pigs.

4.2Indicationsforuse,specifyingthetargetspecies

Treatmentofacuteoutbreaksofrespiratorydiseasecausedbystrainsof

ActinobacilluspleuropneumoniaeandPasteurellamultocidasusceptibleto

florfenicol.

4.3Contraindications

Donotadministertoboarsintendedforbreeding.

Donotuseincaseofhypersensitivitytotheactivesubstanceortoanyofthe

excipients.

Donotuseinthecasesofknownresistancetotheactivesubstance.

4.4 Specialwarnings

None

Revised:March2013

AN:01142/2012

4.5Specialprecautionsforuse

i. Specialprecautionsforuseinanimals

Wipethestopperbeforeremovingeachdose.Useadry,sterilesyringe

andneedle.

Donotuseinpigletsoflessthan2kg.

Theproductshouldbeusedinconjunctionwithsusceptibilitytestingand

takeintoaccountofficialandlocalantimicrobialpolicies.

Useasuitabledraw-offneedleorautomaticdosingsyringetoavoid

excessivepuncturingoftheclosure.

ii. Specialprecautionstobetakenbythepersonadministeringtheveterinary

medicinalproducttoanimals

Careshouldbetakentoavoidaccidentalself-injection.

Inthecaseofself-injection,seekmedicaladviceandshowthelabeltothe

doctor.

Donotusetheproductinknowncasesofsensitivitytoflorfenicol,

propyleneglycolandpolyethyleneglycols.

Incaseofaccidentalcontactwitheyes,rinseimmediatelywithplentyof

water.

4.6Adversereactions(frequencyandseriousness)

Commonlyobservedadverseeffectsaretransientdiarrhoeaand/orperi-analand

rectalerythema/oedemawhichmayaffect50%oftheanimals.Theseeffectscan

beobservedforoneweek.

Transientswellinglastingupto5daysmaybeobservedatthesiteofinjection.

Inflammatorylesionsattheinjectionsitemaybeseenupto28days.

4.7Useduringpregnancy,lactationorlay

Studiesinlaboratoryanimalshavenotrevealedanyevidenceofembryo-or

foeto-toxicpotentialforflorfenicol.However,thesafetyoftheproductinsows

duringpregnancyandlactationhasnotbeendemonstrated.Useoftheproduct

duringpregnancyandlactationisthereforenotrecommended.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Nodataavailable.

4.9Amountstobeadministeredandadministrationroute

15mg/kgbodyweight(1mlper20kg)byintramuscularinjectionintotheneck

muscletwiceat48hourintervalsusingadry,sterile16-gaugeneedle.

Thevolumeadministeredperinjectionsiteshouldnotexceed3ml.

Itisrecommendedtotreatanimalsintheearlystagesofdiseaseandtoevaluate

theresponsetotreatmentwithin48hoursafterthesecondinjection.

Ifclinicalsignsofrespiratorydiseasepersist48hoursafterthelastinjection,

treatmentshouldbechangedusinganotherformulationoranotherantibioticand

continueduntilclinicalsignshaveresolved.

Revised:March2013

AN:01142/2012

Toensureacorrectdosagebodyweightshouldbedeterminedasaccuratelyas

possibletoavoidunderdosing.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Inswineafteradministrationof3timestherecommendeddoseormorea

reductioninfeeding,hydrationandweightgainhasbeenobserved.

Afteradministrationof5timestherecommendeddoseormorevomitinghasalso

beennoted.

4.11Withdrawalperiod

Meatandoffal: 18days

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Antibacterialsforsystemicuse

ATCVetCode:QJ01BA90

5.1Pharmacodynamicproperties

Florfenicolisabroad-spectrumsyntheticantibioticactiveagainstmostGram-

positiveandGram-negativebacteriaisolatedfromdomesticanimals.Florfenicol

actsbyinhibitionofproteinsynthesisattheribosomallevelandisbacteriostatic.

However,bactericidalactivityhasbeendemonstratedin-vitroagainst

ActinobacilluspleuropneumoniaeandPasteurellamultocida.

In-vitrotestinghasshownthatflorfenicolisactiveagainstthebacterialpathogens

mostcommonlyisolatedinrespiratorydiseasesinpigs,includingActinobacillus

pleuropneumoniaeandPasteurellamultocida.

Acquiredresistancetoflorfenicolismediatedbyeffluxpumpresistance

associatedwithafloRgene.Intargetpathogens,suchresistancehasonlybeen

identifiedinPasteurellamultocida.Crossresistancewithchloramphenicolcan

occur.

5.2Pharmacokineticparticulars

Afterasingleintramuscularadministrationoftherecommendeddoseof15mg/kg

maximumplasmaconcentrationsof2.08µg/mlwerereachedafter2hours.

Theharmonicmeaneliminationhalflifewas10.37hours.

Afteradministrationtopigsbytheintramuscularroute,florfenicolisrapidly

excreted,primarilyinurine.Theflorfenicolisextensivelymetabolised.

Serumconcentrationspersistabove1µg/mlfor12to24hoursfollowingIM

administration.Florfenicolconcentrationsachievedinlungtissuereflectplasma

concentrations,withalung:plasmaconcentrationratioofapproximately1.

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Dimethylsulfoxide

Propyleneglycol

Macrogol400

Revised:March2013

AN:01142/2012

6.2Incompatibilities

Intheabsenceofincompatibilitystudies,thisveterinarymedicinalproductshould

notbemixedwithotherveterinarymedicinalproducts.

6.3Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:3years.

Shelf-lifeafterfirstopeningtheimmediatepackaging:28days.

6.4Specialprecautionsforstorage

Thisveterinarymedicinalproductdoesnotrequireanyspecialstorage

conditions.

6.5Natureandcompositionofimmediatepackaging

50,100and250mlTypeIamberglassbottleclosedwithabromobutylrubber

stopperandaluminiumseal.

1bottle(50ml)incardboardbox.

1bottle(100ml)incardboardbox.

1bottle(250ml)incardboardbox.

Notallpacksizesmaybemarketed.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Disposeofanyunusedproductandemptycontainersinaccordancewith

guidancefromyourlocalwasteregulationauthority.

7. MARKETINGAUTHORISATIONHOLDER

KRKA,d.d.,Novomesto

Šmarješkacesta6

8501Novomesto

Slovenia

8. MARKETINGAUTHORISATIONNUMBER

Vm01656/4027

9. DATEOFFIRSTAUTHORISATION

Date:04/07/2007

10.DATEOFREVISIONOFTHETEXT

Date:March2013

Approved:21/03/2013

31-10-2018

Safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos when used as a feed flavouring for all animal species

Safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos when used as a feed flavouring for all animal species

Published on: Tue, 30 Oct 2018 00:00:00 +0100 Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos (hop strobiles) when used as a sensory feed additive for all animal species. The additive is specified to containing 40% beta acids and less than 0.2% alpha acids. Known substances of conce...

Europe - EFSA - European Food Safety Authority Publications

31-10-2018

Efficacy of Bergazym® P100 (endo‐1,4‐β‐xylanase) as a feed additive for chickens for fattening and weaned piglets

Efficacy of Bergazym® P100 (endo‐1,4‐β‐xylanase) as a feed additive for chickens for fattening and weaned piglets

Published on: Tue, 30 Oct 2018 00:00:00 +0100 The product Bergazym® P100 contains a xylanase which is produced by a non‐genetically modified strain of Trichoderma reesei. The additive is available in a coated granular form and it is intended to be used as a zootechnical additive (functional group: digestibility enhancers) for chickens for fattening, and weaned piglets at the dose of 1,500 EPU/kg feed. The production strain and the additive were fully characterised in a previous assessment of the Panel o...

Europe - EFSA - European Food Safety Authority Publications

11-10-2018

Re‐evaluation of oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (E 479b) as a food additive

Re‐evaluation of oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (E 479b) as a food additive

Published on: Wed, 10 Oct 2018 00:00:00 +0200 The EFSA Panel on Food Additives and Flavourings (FAF) provides a scientific opinion re‐evaluating the safety of thermally oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (TOSOM) (E 479b) when used as a food additive. The Scientific Committee on Food (SCF) and the Joint FAO/WHO Expert Committee on Food Additives (JECFA) derived an acceptable daily intake (ADI) of 25 and 30 mg/kg body weight (bw) per day, respectively. There was n...

Europe - EFSA - European Food Safety Authority Publications

13-7-2018

Hospira Issues Voluntary Nationwide Recall of Daptomycin for Injection Lyophilized Powder for Solution, Due to Infusion Reactions

Hospira Issues Voluntary Nationwide Recall of Daptomycin for Injection Lyophilized Powder for Solution, Due to Infusion Reactions

Hospira, Inc., a Pfizer company, is voluntarily recalling 8 lots of Hospira’s Daptomycin for Injection 500 mg, Lyophilized Powder For Solution, Single Dose Vial (NDC 0409-0106-01) to the Hospital/Retail level. The product is being recalled due to adverse event reports indicative of infusion reactions.

FDA - U.S. Food and Drug Administration